Press Releases

Date	Title and Summary	Additional Formats
Toggle SummarySep 22, 2014	Agile to Present at the 21st Annual BioCentury NewsMakers Conference PRINCETON, N.J., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...	Agile to Present at the 21st Annual BioCentury NewsMakers Conference 13.8 KB
Toggle SummaryMar 31, 2022	Agile Therapeutics® Partners with Award-Winning Director Maya Albanese on First Twirla® Commercial, Targeting Gen Z Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal system, while highlighting the power of female friendships PRINCETON, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....	PDF Version
Toggle SummaryApr 7, 2022	Agile Therapeutics® Announces Poster Presentation at the 2022 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that data from the company’s first-year of postmarketing pharmacovigilance...	PDF Version
Toggle SummaryDec 22, 2017	Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the...	Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy 16.6 KB
Toggle SummaryMay 18, 2018	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy PRINCETON, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) held on April 16, 2018 to discuss the complete...	Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for the Prevention of Pregnancy 16.9 KB
Toggle SummaryJan 10, 2019	Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance Discussions with FDA on Design of Comparative Wear Study of Twirla ® and Xulane ® Completed Cash Expected to Enable Company to Fund Operations into Second Quarter of 2019 PRINCETON, N.J. , Jan. 10, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company,...	Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance 38 KB
Toggle SummaryJun 7, 2018	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , June 07, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX), a women’s healthcare company, today announced several key corporate updates: Formal dispute resolution request has been...	Agile Therapeutics, Inc. Provides Corporate Update and Revised Cash Guidance 26.1 KB
Toggle SummaryOct 24, 2018	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) PRINCETON, N.J. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced an oral presentation regarding predictors of pregnancy in the Phase 3 SECURE study of the investigational low-dose, once-weekly contraceptive patch,...	Agile Therapeutics, Inc. Presents Additional Analyses of AG200-15 (Twirla®) Phase 3 SECURE Study Results at the 2018 North American Forum on Family Planning (NAFFP) 34.3 KB
Toggle SummaryDec 13, 2018	Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® Expects to Announce Results of Meeting After Receipt of Final Minutes from FDA PRINCETON, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX), a women’s healthcare company, today announced that on December 11, 2018 , it met with the U.S....	Agile Therapeutics, Inc. Meets With FDA on Comparative Wear Study of Twirla® and Xulane® 34.7 KB
Toggle SummaryFeb 10, 2020	Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors Funding to Support the Company’s Commercialization Plans for Twirla ® PRINCETON, N.J. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit facility with Perceptive...	PDF Version